Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Dianthus Therapeutics (NASDAQ:DNTH) and raises the price target from $33 to $38.
May 10, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico reaffirmed an Outperform rating on Dianthus Therapeutics and increased the price target from $33 to $38, indicating a positive outlook on the company's stock.
The increase in price target by a reputable analyst suggests a strong confidence in Dianthus Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100